Canada's MediPharm Labs reports positive Q1 adjusted EBITDA

Overview

• Canada cannabinoid drugmaker's Q1 revenue was C$9 mln with gross margin of 37%

• Company achieved positive adjusted EBITDA, up from negative in prior quarter

• Operating expenses fell 28% from Q4 2025 due to restructuring and cost control

Outlook

• MediPharm Labs to prioritize margin accretive products and sustainable profitability over short-term opportunities

Result Drivers

• INTERNATIONAL GROWTH - Co said international medical revenue accounted for 51% of total revenue, with new agreements in France and Brazil and sequential revenue growth in Germany

• COST CONTROL - Operating expenses decreased 28% from Q4 2025, reflecting restructuring actions and cost discipline

• PRODUCT MIX - Gross margin of 37% attributed to disciplined product mix and focus on margin-accretive products

Company press release: ID:nGNX2N04ZG

Key Details

Analyst Coverage

• The one available analyst rating on the shares is "hold"

• The average consensus recommendation for the pharmaceuticals peer group is "buy."

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.